Esperion Therapeutics (ESPR) Operating Expenses (2012 - 2026)

Esperion Therapeutics has reported Operating Expenses for 15 years, with the latest figure at $86.7 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses changed 0.47% year-over-year to $86.7 million; the trailing twelve-month figure through Mar 2026 stood at $342.5 million (up 279.55% YoY), and the FY2025 full-year result was $342.9 million, up 399.79% from the prior year.
• Operating Expenses for Q1 2026 stood at $86.7 million, up from $83.2 million in the prior quarter.
• The five-year high for Operating Expenses was $97.3 million in Q3 2025, with the low at -$154.0 million in Q4 2023.
• Historically, Operating Expenses has averaged $46.8 million across 5 years, with a median of $67.7 million in 2024.
• Annual changes were most pronounced in 2023 — Operating Expenses plunged 351.12% — and 2025, when it surged 161.29%.
• Esperion Therapeutics' Operating Expenses stood at $61.3 million in 2022, then sank by 351.12% to -$154.0 million in 2023, then grew by 11.84% to -$135.8 million in 2024, then surged by 161.29% to $83.2 million in 2025, then advanced by 4.17% to $86.7 million in 2026.
• The last three Operating Expenses figures came in at $86.7 million (Q1 2026), $83.2 million (Q4 2025), and $97.3 million (Q3 2025), per Business Quant data.